Outcome of Board Meeting held on May 19, 2026 for approval of standalone and consolidate financial results of the Company for the quarter and year ended March 31, 2026

Pat Growth 25pctExceptional ItemResults View source PDF Explain this filing

ANTHEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.1%Reaction day

₹780.00

prior close

₹801.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.4%-0.4% vs market

Pharmaceuticals & Biotechnology peers, median of 162sector · industry level+0.3%-0.4% vs sector

On the reaction day the stock moved 0.4 pts less than Nifty Midcap 150 and 0.4 pts less than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

+1.0

15m

+0.8

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.1+0.4-0.4+0.3-0.4

Next day

-1.3+0.5-1.8+0.7-2.0

-0.5+0.6-1.1+0.4-1.0

-2.2+1.4-3.7+1.7-3.9

-1.3+1.9-3.1+1.8-3.1

-3.0+2.3-5.3+2.0-5.0

-3.8-0.5-3.4+1.3-5.1

15d

+0.0-2.9+2.9-0.6+0.6

-1.7+3.1-4.8+3.8-5.4

+1.2+3.2-2.0+7.8-6.6

+12.2+4.5+7.6+8.2+3.9

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals & Biotechnology peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Anthem Biosciences reported strong FY2026 results with standalone revenue of ₹2,089 crore (up 13.5% YoY) and consolidated revenue of ₹2,120 crore (up 14.9% YoY). Standalone PAT grew 12.7% to ₹570.6 crore while consolidated PAT surged 30.9% to ₹590.2 crore, driven by robust performance in both standalone and subsidiary operations. The auditor (K.P. Rao & Co.) issued an unmodified (clean) opinion on both standalone and consolidated financials. Exceptional items of ₹240 million (standalone) and ₹244 million (consolidated) were recorded for new labour code provisions. The board recommended a final dividend of ₹2 per share (100% payout on face value) and approved ESOP allotments of 14.81 lakh equity shares. The wholly-owned subsidiary Neoanthem Lifesciences reported a loss of ₹78.7 crore but this did not impact the clean audit opinion.

Likely market impact

Strong financial performance with PAT growth exceeding 25% on consolidated basis. Clean audit with no qualifications is positive. The labour code provisions and subsidiary losses are noted but not material concerns. Dividend declaration signals confidence in cash generation.